Satio and Nanowear have entered a partnership agreement aimed at progressing home-based diagnostic and therapeutic care that ...

Satio and Nanowear today announced that they partnered to advance patient-friendly, home-based diagnostic and therapeutic care.

For Investigational Purposes, Nanowear’s app, platform, and server will transmit Dexcom G7 CGM data, offering first-in-the-world, home-based, self-administered, continuous cardiometabolic ...

Nanowear, a leader in home-based cardiometabolic digital diagnostics announced that SimpleSense™, a nanotechnology-enabled wearable, mobile and software diagnostics platform, will ingest glucose ...

For Investigational Purposes, Nanowear’s app, platform, and server will transmit Dexcom G7 CGM data, offering first-in-the-world, home-based, self-administered, continuous cardiometabolic assessments ...